Trial Profile
A Randomized, Open Label, Multicenter Study Comparing the Safety and Efficacy of Once Daily Regimen Containing Epzicom or Truvada Combined With Ritonavir Boosted Atazanavir as Initial Therapy for HIV-1 Infection (ET Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Lamivudine/abacavir (Primary) ; Atazanavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- 27 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Nov 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 01 Mar 2011 Status changed from recruiting to not yet recruiting as reported by University Hospital Medical Information Network - Japan.